ArticleScientific reports2025
Fatty acid-binding proteins as potential biomarkers for human cancer prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fatty acid-binding proteins (FABPs) play a pivotal role in the malignant progression of numerous human cancers. However, the precise functions of FABP family genes in different cancer types remain incompletely elucidated. The data used in this study were acquired from The Cancer Genome Atlas (TCGA). These data were employed to analyze the expression levels of FABP family genes across different cancer types and their association with sensitivity to anticancer drugs. Survival analysis of FABP family genes was performed using the Kaplan-Meier method. In addition, we investigated the correlation of immune subtypes, tumor microenvironment, and stemness score with pan-cancer. We further explored the role of FABP family genes in hepatocellular carcinoma (HCC), copy number variation patterns, and clinical prognostic value. Finally, we evaluated the expression of FABP family genes in human HCC samples using real-time quantitative PCR. The results showed different degrees of genetic heterogeneity among FABP family members. The expression of FABP varies widely in most cancers and paracancerous tissues, especially BRCA and HCC. The expression of the FABP family is positively correlated with the sensitivity of most anticancer drugs. We discovered the predictive prognostic value of FABP family genes through survival analyses. In pan-cancer, there was a significant variation in the expression of the FABP family across six distinct immunotypes. These genes were strongly associated with immune subtypes, stemness scores, and tumor microenvironment. The pattern of genetic variation of the FABP family in HCC was mainly amplification and deletion, with FABP4, FABP5, FABP9, and FABP12 having significantly higher frequencies of amplified genes than the other members. Our findings provide new guidance for the precision diagnosis and treatment of FABPs in pan-cancer. FABP3 and FABP5 may be potential prognostic factors for HCC, but further research is needed to confirm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.